Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8266547 | 0.83 | SMN1; SMN2 (0.40) | SMN1; SMN2RAB9ANPC1LMNAMAPT | |
| SCHEMBL7609071 | 0.82 | SMN1; SMN2 (0.36) | SMN1; SMN2RAB9ANPC1LMNAMAPT | |
| SCHEMBL18390051 | 0.74 | HTT (0.38) | SMN1; SMN2NPC1LMNAL3MBTL1KDM4E | |
| Ammonia Solution, Strong SCHEMBL28919773 | 0.72 | HTT (0.37) | SMN1; SMN2NPC1LMNAL3MBTL1KDM4E | |
| SCHEMBL370625 | 0.70 | MEN1 (0.44) | RAB9ANPC1MAPTL3MBTL1KMT2A | |
| SCHEMBL17247573 | 0.68 | KDR (0.36) | KMT2AALDH1A1 | |
| SCHEMBL7602975 | 0.66 | LRRK2 (0.33) | RAB9ANPC1 | |
| SCHEMBL15884937 | 0.66 | PDE4D (0.38) | KMT2A | |
| SCHEMBL4552450 | 0.65 | MEN1 (0.45) | RAB9ANPC1MAPTL3MBTL1KMT2A | |
| SCHEMBL23402163 | 0.65 | SMN1; SMN2 (0.48) | SMN1; SMN2RAB9ANPC1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020094989-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | HALE JEFFREY J (US) | 2002-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094989-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | CCR5, CCR1, CXCR1 | SMN1; SMN2 4716/4885RAB9A 310/4885NPC1 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.